Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.

Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children’s Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children’s Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.